PMID- 26650254
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20191210
IS  - 1473-5849 (Electronic)
IS  - 0955-8810 (Linking)
VI  - 27
IP  - 2-3 Spec Issue
DP  - 2016 Apr
TI  - Neurochemical substrates of the rewarding effects of MDMA: implications for the 
      development of pharmacotherapies to MDMA dependence.
PG  - 116-32
LID - 10.1097/FBP.0000000000000210 [doi]
AB  - In recent years, studies with animal models of reward, such as the intracranial 
      self-stimulation, self-administration, and conditioned place preference 
      paradigms, have increased our knowledge on the neurochemical substrates of the 
      rewarding effects of 3,4-methylenedioxymetamphetamine (MDMA) in rodents. However, 
      pharmacological and neuroimaging studies with human participants are scarce. 
      Serotonin [5-hydroxytryptamine (5-HT)], dopamine (DA), endocannabinoids, and 
      endogenous opiates are the main neurotransmitter systems involved in the 
      rewarding effects of MDMA in rodents, but other neurotransmitters such as 
      glutamate, acetylcholine, adenosine, and neurotensin are also involved. The most 
      important finding of recent research is the demonstration of differential 
      involvement of specific neurotransmitter receptor subtypes (5-HT2, 5-HT3, DA D1, 
      DA D2, CB1, mu and delta opioid, etc.) and extracellular proteins (DA and 5-HT 
      transporters) in the acquisition, expression, extinction, and reinstatement of 
      MDMA self-administration and conditioned place preference. It is important to 
      extend the research on the effects of different compounds acting on these 
      receptors/transporters in animal models of reward, especially in priming-induced, 
      cue-induced, and stress-induced reinstatement. Increase in knowledge of the 
      neurochemical substrates of the rewarding effects of MDMA may contribute to the 
      design of new pharmacological treatments for individuals who develop MDMA 
      dependence.
FAU - Roger-Sanchez, Concepcion
AU  - Roger-Sanchez C
AD  - Unit of Research on Psychobiology of Drug Dependence, Department of 
      Psychobiology, Faculty of Psychology, University of Valencia, Valencia, Spain.
FAU - Garcia-Pardo, Maria P
AU  - Garcia-Pardo MP
FAU - Rodriguez-Arias, Marta
AU  - Rodriguez-Arias M
FAU - Minarro, Jose
AU  - Minarro J
FAU - Aguilar, Maria A
AU  - Aguilar MA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Behav Pharmacol
JT  - Behavioural pharmacology
JID - 9013016
RN  - 0 (Hallucinogens)
RN  - 0 (Receptors, Neurotransmitter)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/*metabolism
MH  - Conditioning, Psychological/drug effects
MH  - Hallucinogens/*administration & dosage
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage
MH  - Receptors, Neurotransmitter/metabolism
MH  - *Reward
MH  - Substance-Related Disorders/*drug therapy
EDAT- 2015/12/10 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/12/10 06:00
PHST- 2015/12/10 06:00 [entrez]
PHST- 2015/12/10 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1097/FBP.0000000000000210 [doi]
PST - ppublish
SO  - Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):116-32. doi: 
      10.1097/FBP.0000000000000210.